Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia.

PURPOSE: This randomized phase III trial is studying two different chemotherapy regimens and comparing them to see how well they work in treating adults with acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: 6-Mercaptopurine; Carmustine; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Doxorubicin; Etoposide; Liposomal doxorubicin; Mercaptopurine; Methotrexate; Mitoxantrone; Pegaspargase; Prednisone; Sargramostim; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of one of the following malignancies:

• Acute lymphoblastic leukemia (ALL) of B- or T-cell lineage

• Philadelphia chromosome-positive ALL eligible

• Lymphoblastic lymphoma

• Chronic myelogenous leukemia in lymphoid blast crisis

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• Karnofsky 20-100%

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin no greater than 2.0 mg/dL

• Glucocorticoids for higher bilirubin allowed prior to entry, at principal investigator's discretion

Renal:

• Creatinine no greater than 2.0 mg/dL

• Glucocorticoids or renal radiotherapy for higher creatinine allowed prior to entry, at principal investigator's discretion

Cardiovascular:

• Left ventricular ejection fraction at least 50%

Other:

• Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No prior biologic therapy

Chemotherapy

• No prior chemotherapy

Endocrine therapy

• No prior endocrine therapy

Radiotherapy

• No prior radiotherapy

Surgery

• No prior surgery